{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:32:44Z","timestamp":1790706764996,"version":"4.1.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,22]],"date-time":"2013-01-22T00:00:00Z","timestamp":1358812800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0054918","type":"journal-article","created":{"date-parts":[[2013,1,22]],"date-time":"2013-01-22T17:54:37Z","timestamp":1358877277000},"page":"e54918","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":56,"title":["A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models"],"prefix":"10.1371","volume":"8","author":[{"given":"Hao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Berel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil A.","family":"Bhowmick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Figlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung L.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,1,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","article-title":"Renal cell carcinoma","volume":"373","author":"BI Rini","year":"2009","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-5347(05)67889-5","article-title":"Systemic therapy for renal cell carcinoma","volume":"163","author":"RJ Motzer","year":"2000","journal-title":"J Urol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(09)70380-8","article-title":"Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new","volume":"11","author":"KA Furge","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"14071","DOI":"10.1074\/jbc.R109.094003","article-title":"Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony","volume":"285","author":"KG Foster","year":"2010","journal-title":"J Biol Chem"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"R Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"BD Manning","year":"2007","journal-title":"Cell"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1038\/onc.2010.139","article-title":"Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy","volume":"29","author":"CA Sparks","year":"2010","journal-title":"Oncogene"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"G Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors","volume":"116","author":"RJ Motzer","year":"2010","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"RJ Motzer","year":"2008","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1200\/JCO.2006.10.5916","article-title":"Phase I\/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma","volume":"25","author":"RJ Motzer","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","article-title":"Resistance to targeted therapy in renal-cell carcinoma","volume":"10","author":"BI Rini","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity","volume":"70","author":"CM Chresta","year":"2010","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"ME Feldman","year":"2009","journal-title":"PLoS Biol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"MR Janes","year":"2010","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/BJ20090489","article-title":"Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)","volume":"421","author":"JM Garcia-Martinez","year":"2009","journal-title":"Biochem J"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","article-title":"mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways","volume":"10","author":"PK Majumder","year":"2004","journal-title":"Nat Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1038\/sj.onc.1210245","article-title":"A gene transcription signature of the Akt\/mTOR pathway in clinical breast tumors","volume":"26","author":"CJ Creighton","year":"2007","journal-title":"Oncogene"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, <etal>et al<\/etal>. (2010) Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One 5: e10696. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.plosone.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pone.0010696\" xlink:type=\"simple\">http:\/\/www.plosone.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pone.0010696<\/ext-link>. Accessed: 21 December 2012.","DOI":"10.1371\/journal.pone.0010696"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1073\/pnas.091062498","article-title":"Significance analysis of microarrays applied to the ionizing radiation response","volume":"98","author":"VG Tusher","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4161\/auto.4600","article-title":"How to interpret LC3 immunoblotting","volume":"3","author":"N Mizushima","year":"2007","journal-title":"Autophagy"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/1087057109355059","article-title":"Maximizing RNA yield from archival renal tumors and optimizing gene expression analysis","volume":"15","author":"ST Glenn","year":"2010","journal-title":"J Biomol Screen"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Glenn ST, Jones CA, Liang P, Kaushik D, Gross KW, <etal>et al<\/etal>. (2007) Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers. Biotechniques 43: 639\u2013640, 642\u2013633, 647.","DOI":"10.2144\/000112562"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/1078-0432.CCR-07-0781","article-title":"Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma","volume":"13","author":"JG Kuhn","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"M Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.gde.2006.12.006","article-title":"Hypoxia-inducible factors: central regulators of the tumor phenotype","volume":"17","author":"JD Gordan","year":"2007","journal-title":"Curr Opin Genet Dev"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrurol.2010.47","article-title":"The genetic basis of kidney cancer: a metabolic disease","volume":"7","author":"WM Linehan","year":"2010","journal-title":"Nat Rev Urol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"34495","DOI":"10.1074\/jbc.C800170200","article-title":"Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2","volume":"283","author":"A Toschi","year":"2008","journal-title":"J Biol Chem"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","article-title":"Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth","volume":"1","author":"K Kondo","year":"2003","journal-title":"PLoS Biol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(02)00044-2","article-title":"The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma","volume":"1","author":"JK Maranchie","year":"2002","journal-title":"Cancer Cell"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-09-3022","article-title":"The efficacy of the novel dual PI3-kinase\/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma","volume":"16","author":"DC Cho","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/hmg\/10.10.1019","article-title":"von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF","volume":"10","author":"MA Hoffman","year":"2001","journal-title":"Hum Mol Genet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1074\/jbc.270.5.2320","article-title":"Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes","volume":"270","author":"EF Blommaart","year":"1995","journal-title":"J Biol Chem"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ceb.2009.11.005","article-title":"TOR-dependent control of autophagy: biting the hand that feeds","volume":"22","author":"TP Neufeld","year":"2010","journal-title":"Curr Opin Cell Biol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1074\/jbc.M111.304485","article-title":"Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics","volume":"287","author":"Q Liu","year":"2012","journal-title":"J Biol Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ddstr.2009.12.001","article-title":"mTOR Mediated Anti-Cancer Drug Discovery","volume":"6","author":"Q Liu","year":"2009","journal-title":"Drug Discov Today Ther Strateg"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/bjc.2011.15","article-title":"Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines","volume":"104","author":"Y Wang","year":"2011","journal-title":"Br J Cancer"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0054918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T14:54:03Z","timestamp":1540220043000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0054918"}},"subtitle":[],"editor":[{"given":"Soumitro","family":"Pal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0054918","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,22]]}}}